The New Yorker just lab-tested research peptides from a popular online vendor. BPC-157: contained lead. TB-500: contained endotoxins. CJC-1295: less than 42% of the labeled dose. This is what people are injecting into their bodies. The peptides aren't the problem. The supply chain is. This is exactly why the FDA reclassification matters moving these compounds into regulated compounding pharmacies with cGMP standards and real quality control.

eNavvi’s formulary now spans multiple therapeutic categories—giving providers a single platform to explore compounding options across their entire practice. Available categories may include: • Hormone therapy — formulations for men’s and women’s hormonal health • Dermatology — topical preparations for skin health needs • Pain management — topicals, transdermals, and alternative delivery methods • Sexual health — formulations for both male and female patients • Peptide therapy — preparations available through accredited pharmacies as regulatory frameworks evolve Every formulation on the platform comes from an accredited pharmacy with transparent pricing visible before you prescribe. One platform. Multiple specialties. Full transparency.

When a commercial medication is discontinued, patients don’t always have a clear next step. It happens more often than most people realize. Manufacturers discontinue products for commercial reasons—not clinical ones. Patients who were stable on a medication may suddenly find themselves without access to the formulation that was working for them. Compounded medications may offer a path forward in these situations. Accredited compounding pharmacies can prepare formulations under a clinician’s direction that may help address gaps left by discontinued commercial products. This isn’t about replacing FDA-approved medications. It’s about ensuring patients have options when the commercial supply chain falls short. No patient should lose access to care because of a business decision they had no part in.

Men’s health is one of the fastest-growing categories in compounding—and one of the most underserved in traditional pharmacy. Compounded formulations may offer clinicians flexibility across a range of men’s health needs: hormonal optimization, sexual health, hair restoration, and urological support. Delivery methods can include topicals, injectables, sublingual preparations, and oral formulations—tailored to each patient’s clinical profile. On eNavvi, providers can browse available men’s health formulations from accredited compounding pharmacies, compare options with transparent pricing, and prescribe digitally—all within a single platform. Whether you’re an endocrinologist, urologist, or primary care provider exploring compounded options for male patients, the formulary is built for clinical flexibility. Every patient’s needs are different. The treatment plan should reflect that. Explore men’s health formulations at eNavvi.com

The FDA's Category 2 list restricted 19 peptides from compounding. Now, approximately 14 of them may be coming back. HHS has signaled that peptides previously barred from compounding — spanning categories like tissue repair, immune modulation, metabolic support, cognitive health, and hormonal signaling — could be reclassified to Category 1, restoring access through licensed compounding pharmacies under physician supervision. What this does not mean: FDA approval. These remain off-label therapeutics that require clinical oversight, proper dosing, and ongoing monitoring. What it does mean: prescribers may soon have access to a broader range of compounded peptide formulations — but only through accredited pharmacies with transparent sourcing and quality controls. The regulatory landscape is shifting. The need for physician-guided, compliance-first prescribing is not. Stay informed and explore available formulations at eNavvi.com

The FDA's Category 2 list restricted 19 peptides from compounding. Now, approximately 14 of them may be coming back. HHS has signaled that peptides previously barred from compounding — spanning categories like tissue repair, immune modulation, metabolic support, cognitive health, and hormonal signaling — could be reclassified to Category 1, restoring access through licensed compounding pharmacies under physician supervision. What this does not mean: FDA approval. These remain off-label therapeutics that require clinical oversight, proper dosing, and ongoing monitoring. What it does mean: prescribers may soon have access to a broader range of compounded peptide formulations — but only through accredited pharmacies with transparent sourcing and quality controls. The regulatory landscape is shifting. The need for physician-guided, compliance-first prescribing is not. Stay informed and explore available formulations at eNavvi.com

Nearly 50 million Americans live in a pharmacy desert. But even for patients with a pharmacy nearby, access barriers persist. Insurance formulary restrictions. Prior authorization delays. Commercial medications discontinued without notice. Dosage strengths that don’t match clinical needs. These aren’t edge cases. They’re everyday realities for millions of patients navigating a system that wasn’t built around their individual needs. Compounded medications exist to fill these gaps—prepared by accredited pharmacies under a clinician’s direction, tailored to the specific requirements of each patient. When the standard options fall short, patients deserve to know that alternatives may be available. That conversation starts with their provider. Help your patients understand their options.

Chronic pain affects an estimated 51 million adults in the U.S.—and for many, commercial medication options may not fully address their individual needs. Compounded pain management formulations may offer clinicians additional flexibility. Topical preparations, for example, can be tailored to combine multiple active ingredients in a single application, potentially reducing the need for systemic medications. This is especially relevant as prescribers increasingly seek alternatives that may help manage pain while minimizing systemic exposure. Compounded topicals, transdermals, and other delivery methods give providers additional tools in their clinical toolkit. Every patient’s pain profile is different. The treatment approach should reflect that. Through eNavvi, providers can explore available pain management formulations from accredited pharmacies with transparent pricing and digital prescribing. Discuss compounded options with your healthcare provider

What if every compound prescription started with full pricing visibility? That’s the principle behind eNavvi’s digital formulary. Before a clinician sends a single prescription, they can: • See transparent cash pricing across a network of accredited compounding pharmacies • Compare formulations, delivery methods, and availability in real time • Send the prescription digitally—securely, compliantly, in under 60 seconds No hidden costs. No after-the-fact pricing surprises. The platform is free for clinicians and designed by physicians who lived the workflow challenges of compound prescribing. See pricing transparency in action at eNavvi.com

The median compounding pharmacy works with 150 different prescribers and dispenses 100 unique formulations per week. That’s a level of specialization most providers never see from their traditional pharmacy relationships. If you’re new to compound prescribing, here’s what to know: • Compounding is patient-specific—each preparation is made based on a clinician’s prescription for an individual patient • Accredited pharmacies follow USP standards that govern quality, sterility, and safety • Digital platforms can simplify the process—from browsing formulations to comparing pricing to sending prescriptions electronically The workflow doesn’t have to be complicated. The right tools make it seamless. Explore how it works at eNavvi.com

Hormone therapy accounts for an estimated 36% of all compounded prescriptions dispensed in the U.S.—making it the single largest category in compounding. Why? Because hormone management is inherently individual. Patients may present with needs that commercially available formulations don’t fully address—whether that involves specific dosage strengths, alternative delivery methods, or ingredient sensitivities. Compounded hormone preparations may offer clinicians additional flexibility to tailor treatments to each patient’s clinical profile, in consultation with their care team. Through eNavvi, providers can explore available hormone therapy formulations from accredited pharmacies, compare transparent pricing, and prescribe digitally. Discuss compounded hormone options with your healthcare provider. Learn more at eNavvi.com

CMS just selected 15 new drugs for Medicare price negotiation—including, for the first time, drugs covered under Part B. At the same time, the Department of Labor extended its comment period on PBM fee disclosure rules through April 15. The message from regulators is clear: transparency in drug pricing is no longer aspirational. It’s becoming structural. For compounded medications—where cash-pay prescribing is often the norm—pricing visibility has always been the gap. Providers shouldn’t have to guess what a patient will pay. eNavvi brings that visibility to the compound prescribing workflow, so clinicians and patients can make informed decisions together. Transparency is the direction the industry is moving. We’re already there. Learn more at eNavvi.com

Personalized medicine is no longer a future promise. It’s a present reality. The compounding pharmacy market is projected to exceed $34 billion by 2035. The driver? Patients and providers increasingly seeking treatments tailored to individual needs—not mass-produced for the average case. But personalization requires infrastructure: accredited pharmacies, transparent pricing, compliant prescribing workflows, and digital tools that make it all accessible. Without that infrastructure, personalized medicine remains a concept. With it, it becomes standard practice. The providers building personalized care today are the ones shaping healthcare tomorrow. What role does compounding play in your practice? We’d love to hear. Visit eNavvi.com

Nearly 29% of U.S. pharmacies closed between 2010 and 2021. Rural communities were hit hardest. For patients in pharmacy deserts, accessing even basic medications can mean driving hours. Compounded medications—which may require specialized preparation—can be even harder to obtain. Digital prescribing platforms are helping close this gap. When clinicians can browse accredited pharmacy networks online, compare pricing, and route prescriptions digitally, geography becomes less of a barrier. Every patient deserves access to the care their provider recommends—regardless of zip code. Learn how digital prescribing expands access at eNavvi.com

Thinking about prescribing compounded medications? Here are three questions to ask before choosing a pharmacy partner. 1. Are they accredited? Look for PCAB or NABP accreditation—the recognized standards for compounding quality and safety. 2. Do they comply with USP standards? USP chapters 795, 797, and 800 govern non-sterile, sterile, and hazardous drug compounding, respectively. 3. Can you see pricing before you prescribe? Transparent cash pricing protects both your patients and your practice from unexpected costs. eNavvi’s platform is designed to help clinicians answer all three questions before a single prescription is sent. Informed prescribing starts with the right tools. Explore eNavvi.com

Dermatology is one of the most common—and most personalized—areas of compounded prescribing. Many patients present with skin conditions that may benefit from customized topical formulations. Compounding allows clinicians to work with accredited pharmacies to tailor preparations—adjusting vehicles, concentrations, or ingredient combinations based on individual patient needs. Whether a patient has sensitivities to commercially available inactive ingredients or requires a formulation not available off the shelf, compounded dermatology options may offer an alternative worth discussing. Through eNavvi, clinicians can explore available compounded dermatology formulations, compare transparent cash pricing, and prescribe digitally—all from a single platform. Consult your clinical judgment. Explore options at eNavvi.com

Drugmakers raised prices on more than 350 medications entering 2026—up from 250 at the same point last year. Meanwhile, U.S. patients continue to pay nearly three times more for prescriptions than patients in other developed nations. This is why transparent, cash-pay prescribing tools matter. When providers can see real-time medication costs before prescribing, patients gain the information they need to make informed decisions with their care team. eNavvi was built to bring that visibility to every prescribing interaction—especially for compounded medications, where pricing has historically been among the most opaque in all of healthcare. Transparency starts at the point of care. Not after the fact. Learn more at eNavvi.com

eNavvi now connects prescribers to compounding pharmacies in all 50 states through a single login. Here’s what that means in practice: • Browse 150 pre-formulated compounds across HRT, dermatology, urology, and more • Compare real-time cash prices from multiple PCAB-accredited pharmacies • Send digital prescriptions in under 60 seconds—no fax, no phone calls Our network includes all PCAB-accredited compounding partners Drugs pharmacy network—all vetted for accreditation and compliance. One platform. Nationwide reach. Total transparency. Start prescribing free at eNavvi.com

Not all compounding pharmacies are created equal. Here’s how to tell the difference. With the FDA tightening enforcement on compounded medications, knowing your pharmacy partner’s credentials has never been more important. What to look for: • PCAB or NABP accreditation—the gold standard for quality compounding • Multi-state licensure for nationwide prescribing flexibility • USP 795/797/800 compliance for non-sterile, sterile, and hazardous drug handling eNavvi does this vetting for you. Every pharmacy in our network meets these standards before a single prescription is routed through our platform. Stop guessing. Start prescribing with confidence. Explore our vetted network at eNavvi.com

Two weeks ago, Congress passed landmark PBM reform. The FTC settled with Express Scripts. And TrumpRx.gov launched a direct-to-patient drug platform. Three seismic shifts in prescription drug pricing—all within the same week. The message is clear: the era of opaque drug pricing is ending. But legislation alone won’t fix the system. Providers need tools that deliver transparency at the point of prescribing—not years from now when regulations take effect, but today. That’s what eNavvi was built for. Physician-founded. Transparency-first. Available now. The question isn’t whether transparent prescribing is coming. It’s whether you’re already there. See what transparent prescribing looks like at eNavvi.com